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KRAS status serves as a predictive biomarker of response to treatment in metastatic colorectal 
cancer (mCRC). We hypothesize that complex interactions between multiple pathways contribute 
to prognostic differences between KRAS wild‑type and KRAS mutant patients with mCRC, and 
aim to identify polymorphisms predictive of clinical outcomes in this subpopulation. Most pathway 
association studies are limited in assessing gene–gene interactions and are restricted to an individual 
pathway. In this study, we use a random survival forests (RSF) method for identifying predictive 
markers of overall survival (OS) and progression‑free survival (PFS) in mCRC patients treated with 
FOLFIRI/bevacizumab. A total of 486 mCRC patients treated with FOLFIRI/bevacizumab from two 
randomized phase III trials, TRIBE and FIRE‑3, were included in the current study. Two RSF approaches 
were used, namely variable importance and minimal depth. We discovered that Wnt/β‑catenin 
and tumor associated macrophage pathway SNPs are strong predictors of OS and PFS in mCRC 
patients treated with FOLFIRI/bevacizumab independent of KRAS status, whereas a SNP in the sex‑
differentiation pathway gene, DMRT1, is strongly predictive of OS and PFS in KRAS mutant mCRC 
patients. Our results highlight RSF as a useful method for identifying predictive SNPs in multiple 
pathways.
Approximately 30–40% of colorectal cancers (CRC) harbor activating mutations in Kirsten Ras (KRAS) proto-
oncogene, which encodes for a GTPase transductor protein downstream of epidermal growth factor receptor 
(EGFR) as part of the RAS/RAF/MAPK  pathway1. Activating KRAS mutations are an established predictive 
biomarker for resistance to anti-EGFR therapies in mCRC. Hence, anti-EGFR therapy is currently used alongside 
chemotherapy to treat mCRC with wild-type KRAS, whereas the standard of treatment for KRAS mutant patients 
is chemotherapy with anti-vascular endothelial growth factor (VEGF) monoclonal antibody,  bevacizumab2.
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Although KRAS status has predictive utility, its prognostic role in CRC remains controversial. Colorectal 
carcinogenesis and treatment responses are a result of complex interactions between multiple genes and pathways. 
The KRAS protein has a non-linear interaction with different upstream mediators, including receptor tyrosine 
kinases and growth  factors3, which adds to the complexity of understanding its role in cancer development 
and developing effective treatments. It is possible that focusing on KRAS mutations alone, without considering 
intersecting pathways, is creating barriers in understanding its prognostic value.
Our previous work used genome-wide association studies and Cox-proportional hazard (CPH) models to 
identify significant differences in predicting survival outcomes in mCRC patients from individual clinical cohorts 
based on genetic polymorphisms in pathways regulating angiogenesis. However, CPH has several restrictions, 
for it requires restrictive proportional hazard assumptions, and cannot identify unknown non-linear interactions 
between genetic pathways or incorporate high-dimensional information found in genomic  studies4. In this study, 
we apply a machine learning method, random survival forests (RSF), for identifying predictive polymorphisms 
from multiple pathways.
Random survival forests (RSF) is a non-parametric ensemble tree learning method that has become increas-
ingly popular for genetic and gene expression data  analyses5. It has been successfully applied to cancer staging 
and integrative genomic modelling. In contrast to the CPH model, RSF is an automated approach to identify 
non-linear multivariate effects, even among highly correlated subsets of covariates, which is particularly use-
ful in high-dimensional feature selection problems. An RSF ensemble comprises randomly grown recursively 
partitioned binary trees. Each tree is grown from an independent bootstrap sample, and during the tree growing 
process, each node is split using a randomly selected subset of variables. These properties make it an attractive 
tool for the analysis of complex survival  data4.
Hence, in this study, we illustrate the utility of random survival forests (RSF) in integrating complex interac-
tions and uncovering polymorphisms in multiple pathways predictive of survival in mCRC patients based on 
their KRAS status.
Materials and methods
Study population. A total of 486 patients with mCRC enrolled in two multi-institutional open-label ran-
domized phase III trials: TRIBE (NCT00719797)6 and FIRE-3 (NCT00433927)7 were included in the current 
study. The TRIBE trial compared efficacy of FOLFOXIRI/bevacizumab with FOLFIRI/bevacizumab in both 
KRAS mutant and wild-type mCRC patients. The FIRE-3 trial compared efficacy of FOLFIRI/cetuximab to 
FOLFIRI/bevacizumab as first-line treatment in KRAS wild-type mCRC patients. We combined patients from 
the two cohorts treated with the same regimen: first-line FOLFIRI/bevacizumab and excluded patients in the 
other arms.
Eligibility criteria of our study included patients with histologically proven colorectal adenocarcinoma, meas-
urable metastatic disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and no prior 
systemic chemotherapy for metastatic disease. Selected patients with samples available for analyzing genomic 
DNA were eligible for this study: 189 patients with sufficient samples from TRIBE (75% of 253 enrolled patients) 
and 297 patients with sufficient samples from FIRE-3 (87% of 343 enrolled patients).
All patients signed an informed consent form before enrollment in the randomized trials which included 
information regarding the use of their blood or tumor tissue to explore relevant molecular biomarkers. The cur-
rent study complied with the REporting recommendations for tumor MARKer prognostic studies (REMARK). 
The specimen analysis was approved by the University of Southern California (USC) Institutional Review Board 
of Medical Sciences and carried out at the USC/Norris Comprehensive Cancer Center in adherence with the 
Declaration of Helsinki and Good Clinical Practice Guidelines.
Selected polymorphisms and genotyping. Twenty-seven candidate single nucleotide polymorphisms 
(SNPs) within genes involved in Wnt (AXIN2, TCF7L2, SOX9, CBP, CTNNB1), angiogenesis (EGFL7, VEGFR1, 
VEGFR2 RGS5, PDGFRβ, CSPG4, RALBP1), HIPPO (DSCR1), tumor-associated macrophage (TAM) (HRG, 
CL2, TBK1), tumor budding (CXCR4, MMP2), autophagy (FIP200), EGFR (EPS15, KSR1, KSR2), and sex-
differentiation (FOXL2, DMRT1) pathways were selected according to two major criteria: minor allele frequency 
(MAF) in Caucasians ≥ 10% (www. ensem bl. org); and potential role in changing gene function based on litera-
ture review and public databases (https:// snpin fo. niehs. nih. gov; https:// www. ncbi. nlm. nih. gov). Linkage dis-
equilibrium among selected SNPs was identified through SNAP search service (http:// archi ve. broad insti tute. 
org/ mpg/ snap/).
Genomic DNA was extracted from whole blood of patients enrolled in TRIBE using the QIAamp DNAeasy Kit 
(Qiagen) and from formalin-fixed paraffin-embedded (FFPE) tissues of patients enrolled in FIRE-3. DNA extrac-
tion procedures were according to the manufacturer’s specifications. DNA sequences were analyzed using the ABI 
Sequencing Scanner version 1.0 (Applied Biosystems). Investigators performing in SNP analyses were blinded 
to patients’ clinical data. Genotyping was successful in at least 90% of samples in each polymorphism analyzed.
KRAS mutation analysis. In both trials, mutational analysis of KRAS codons 12, 13, and 61 was con-
ducted using a pyrosequencing approach, and analyzed using PyroMark Q24 1.0.9  software8. However, FIRE-3 
only included patients who were KRAS wild-type at codons 12 and  137.
Statistical analysis. The clinical endpoints of this study were progression-free survival (PFS) and overall 
survival (OS). PFS was defined as period from the first day of randomization start to the first observation of 
disease progression or death from any cause. OS was calculated from the first day of randomization start to the 
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date of death by any cause. Patients were censored at the date of last follow up if there was no event observed. 
RSF was used to identify potential predictors for OS and PFS in mCRC patients with wild-type or mutant KRAS.
For each RSF model, a survival forest with 1000 trees was constructed, and each tree was drawn from a 
random bootstrap sample that excluded on average 37% of the analyzed data, called out-of-bag (OOB) data. 
Each tree was grown starting from a set of randomly selected candidate variables until final node’s size reached a 
minimum number of events with unique survival times. At each node, random candidate variables were selected, 
and the brunch was split using the set of variables that maximized the log-rank statistics, to split the brunch 
these variables. The importance of a variable is measured by minimal depth (MD), which is the depth when the 
variable first splits within a tree, relative to the root  node9. The most predictive variables are identified as those 
with smallest MD values, which means they split the branches close to the tree trunk. The variable selection 
threshold is defined as the mean of the minimal depth distribution among all forests, classifying variables with 
minimal depth lower than this threshold as important in forest prediction.
The cumulative hazard function (CHF) was calculated for each tree and then the ensemble CHF was obtained 
by averaging CHF. Harrell’s concordance index (C-index) using OOB data were used to evaluate the accuracy for 
each RSF model. The prediction accuracy for the Cox proportional hazard models including top 5 identified SNPs 
from RSF models was also evaluated by Harrell’s C-statistics using OOB error rate with 1000 bootstrap samples.
Results
Patient characteristics. A total of 486 patients were included in this study, and their baseline characteris-
tics are shown in Table 1. Of these, 345 patients were KRAS wildtype, and 141 were KRAS mutant.
SNPs and outcomes. The allelic frequencies for all polymorphisms were within the probability limits of 
Hardy–Weinberg equilibrium.
Figures 1, 2, 3 and 4 depict minimal depth analysis of the 27 SNPs analyzed for PFS and OS in KRAS wildtype 
and mutant patients. The dashed vertical line in each figure is the threshold of maximum value for variable 
selection and separates the predictive markers from the remaining non-predictive markers. Low minimal depth 
indicates important markers. In the KRAS wildtype patients, three SNPs with minimal depth are CBP rs129963, 
HRG rs2228243, and TBK1 rs7486100, which are obviously to be the most predictive markers for PFS. Whereas, 
CBP rs129963, TBK1 rs7486100, and VEGFR2 rs2305948 are the most predictive markers for OS. C-index were 
0.50 and 0.44 for PFS and OS respectively. In KRAS mutant patients, β-catenin rs3864004, CBP rs129963, TBK1 
rs7486100, and DMRT1 rs755383 are the top predictors for PFS; β-catenin rs3864004, MMP2 rs243865, and RGS5 
Table 1.  Baseline comparisons between KRAS wildtype and KRAS mutant patients. † p value was based on 
Chi-square test. *Unknown group was not included in the analysis.




p  value†N % n %
Cohort < 0.001
 TRIBE arm A 96 28 93 66
 FIRE3 Bev arm 249 72 48 34
Gender 0.39
 Male 220 64 84 60
 Female 125 36 57 40
Age (years)
 Median (range) 63 (29–76) 62 (33–75)
 ≤ 65 189 55 83 59 0.41
 > 65 156 45 58 41
Performance status 0.004
 ECOG 0 212 61 106 75
 ECOG ≥ 1 133 39 35 25
Primary tumor site 0.75
 Right-sided colon 84 25 23 27
 Left-sided colon 251 75 63 72
 Unknown* 10 55
Primary tumor resected 0.099
 Yes 280 81 105 74
 No 65 19 36 26
Adjuvant chemotherapy 0.39
 Yes 60 17 20 14
 No 285 83 121 86
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rs1056515 are most predictive for OS. C-index were 0.55 and 0.45 for PFS and OS, respectively. To compare the 
RFS model to a Cox proportional hazard models, the top 5 important SNPs selected from each RSF model were 
used to build a Cox model. In KRAS wildtype patients, the C-index for the Cox models was 0.32 for PFS, and 
0.39 for OS; in KRAS mutant patients, the C-indexes were 0.55 and 0.33 for PFS and OS, respectively.
Compare identified SNPs with previous findings by pathways. All top 5 identified SNPs are sum-
marized in Table 2 according to their pathways. The numbers indicate their ranks from minimal depth results.
Wnt PATHWAY SNPs. Previously published work from our lab using CPH models did not identify significant 
associations between Wnt pathway SNPs and OS or PFS in mCRC patients treated with FOLFIRI/bevacizumab 
in individual clinical  trials10,11. Using RSF MD analysis in the current study of combined FOLFIRI/bevacizumab 
arms from TRIBE and FIRE3 trials, CBP rs129963 and β-catenin rs3864004 are shown to be most predictive 
markers for OS in KRAS wildtype and mutant patients, respectively. The non-parametric analysis Kaplan–Meier 
plot and log-rank test for Wnt SNPs are shown in Fig. 5. KRAS wildtype patients with CBP rs129963 T/T variant 
showed significantly shorter OS compared to those with Any C allele (p = 0.048). KRAS mutant patients harbor-
ing β-catenin rs3864004 A/A genotype also showed significantly shorter OS (p = 0.008).
Tumor-associated macrophages (TAM) pathway SNPs. RSF analysis identified TBK1 rs7486100 to be a strong 
predictor for PFS and OS in KRAS wildtype patients, and for PFS in KRAS mutant patients. In addition, HRG 
Figure 1.  Minimal depth plot of 27 SNPs predicting PFS in KRAS wild-type mCRC patients. The most 
predictive SNPs in order of importance are CBP rs129963, HRG rs2228243 and TBK1 rs7486100.
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rs2228243 and CCL2 rs4586 are also top predictors for PFS and OS, respectively, in KRAS wildtype patients. 
Figure 6 showed the Kaplan–Meier plots for TAM SNPs. Wildtype patients with any T allele of TBK1 rs7486100 
showed shorter PFS and OS (p = 0.020 and 0.040, respectively); whereas mutant patients with T/T variant 
had shorter PFS (p = 0.005). Although HRG rs2228243 was identified as a top marker for OS in KRAS mutant 
patients, the log-rank test was not significant (p = 0.45, plot not shown). Furthermore, the wildtype patients with 
Any C allele had shorter OS compared to those with T/T variant (p = 0.006). From our previous work, TBK1 
rs7486100 was shown to predict OS in KRAS mutant, and CCL2 rs4586 to predict PFS in KRAS wildtype patients 
from single arm  analysis12.
Angiogenesis pathway SNPs. The results showed VEGFR2 rs2305948 as a top predictor for OS in wildtype 
patients. KM plot showed that patients with T/T allele had shorter OS than those with Any C allele (p = 0.001) 
(Fig. 7). Although RGS5 rs1056515 was also one of top identified SNPs for OS in mutant patients, log-rant test 
was not significant (p = 0.16, plot not shown). Previous study performed in TRIBE and PROVETTA didn’t iden-
tify these SNPs, subgroup analysis by KRAS mutation status was not conducted either.
Sex-differentiation pathway SNP. DMRT1 rs755383 was one of top predictors for PFS in KRAS mutant patients 
in RSF analysis. Patients with C/C variant had shorter PFS than those with Any T allele (p = 0.037) (Fig. 8). 
Whereas the previous findings based on FIRE3 study showed this SNP to be significant for PFS in KRAS 
wildtype  patients13.
Figure 2.  Minimal depth plot of 27 SNPs predicting OS in KRAS wild-type mCRC patients. The most 
predictive SNPs in order of importance are CBP rs129963, TBK1 rs7486100 and VEGFR2 rs2305948.
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Tumor budding pathway SNPs. In our current study, a SNP in the tumor budding pathway, MMP2 rs243865, 
was a strong predictor of OS in KRAS mutant patients. KM plot showed that patients with any T had a longer OS 
than those with C/C variant (p = 0.021, Fig. 9). This SNP was not identified as a predictive marker in our previous 
analysis in the bevacizumab-based chemotherapy treated patients from TRIBE arm A and PROVETTA  trial13.
Discussion
Our previous studies were mostly focused on candidate polymorphisms selected from a single pathway, and tested 
their association with clinical outcomes in a single treatment arm from a randomized clinical trial. These analyses 
were usually criticized with low statistical power. In this study, we combined the same treatment arms from two 
independent clinical trials, and performed random survival forest analysis for candidate SNPs from different 
pathways. Random forest has been applied broadly as a traditional machine learning method for classification 
and regression, and RSF is a new extension of RF to survival outcome data. It has been applied in several real-
world studies such as GWAS  study14 and systolic heart  research15. The conventional regression-based methods 
to analyze survival data usually rely on restrictive assumptions such as proportional hazards in CPH regression 
models. In addition, the identifying interactions between variables is a common problem when building the 
regression model. In contrast, RSF method can handle these difficulties automatically using ensembled survival 
trees. RSF randomly draws bootstrap sample from data to grow survival tree, and at each node, a subset of ran-
domly selected variables is chosen as candidate variables to split the truck. As such this method does not need 
to select candidate variables in advance like conventional methods. In our study, the general prediction accuracy 
of RSF models is higher than the conventional CPH models. In KRAS wildtype patients, the OOB C-indexes for 
Figure 3.  Minimal depth plot of 27 SNPs predicting PFS in KRAS mutant mCRC patients. The most predictive 
SNPs in order of importance are b-catenin rs3864004, CBP rs129963, TBK1 rs7486100, DMRT1 rs755383.
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PFS and OS are 0.50 and 0.44, respectively from RSF, compared to 0.32 and 0.39 from CPH models; in KRAS 
mutant patients, the C-indexes are 0.55 and 0.45 for PFS and OS, respectively from RSF, compared to 0.55 and 
0.33 from CPH models.
High-throughput genomic technologies, such as single nucleotide polymorphism arrays have revolutionized 
CRC research by making it possible to identify biomarkers across the genome. However, detecting meaningful 
signals and making appropriate inferences from these massive datasets continues to pose challenges because 
of the high dimensionality and complex gene–gene interactions. We believe these complex gene–gene interac-
tions underlie the poorly understood differences between KRAS wildtype and KRAS mutant mCRC patients. 
In this study, we used the high-dimensional power of RSF to identify pathways which could serve as predictive 
biomarkers in mCRC depending on KRAS status.
This is the first study to report that SNPs in the Wnt/β-catenin and TAM pathways are strongly predictive of 
OS and PFS in mCRC patients treated with FOLFIRI/bevacizumab independent of KRAS status. Wnt signaling 
results in β-catenin translocating to the nucleus and recruiting cyclic AMP response-element binding protein 
(CBP) to generate an active transcription  complex16. Once activated, it regulates target gene expression by binding 
to the T-cell factor (TCF)/lymphoid enhancer factor family of transcription  factors17. Glycogen synthase kinase 
3-β (GSK-3β) and a multi-protein complex consisting of AXIN, APC and Diversin regulate phosphorylation 
of β-catenin, which targets it for ubiquitination and  degradation18. The balance between β-catenin stabilization 
and degradation maintains cellular homeostasis.
Figure 4.  Minimal depth plot of 27 SNPs predicting OS in KRAS mutant mCRC patients. The most predictive 
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Aberrant regulation of the Wnt signaling pathway is an established mechanism of colorectal carcinogenesis, 
however, its association with KRAS status is controversial. In this study, CBP and β-catenin were predictive of OS 
and PFS independent of KRAS status. Our results are in contrast with previous reports showing that oncogenic 
KRAS signaling stimulates Wnt pathway, which in turn promotes intestinal tumor growth and  invasion19,20. 
Although KRAS hyperactivates Wnt signaling via TAK1  kinase21, there is considerable heterogeneity in the 
accumulation of nuclear β-catenin, suggesting the role of alternate pathways in influencing β-catenin distribu-
tion and Wnt pathway activation in CRC 19.
Our study shows the close proximity of TAM and Wnt pathway SNPs on the minimal depth plots, which could 
highlight a possible interaction between the two pathways. Macrophages have two main phenotypes, M1 (tumor 
suppressive) and M2 (tumor-promoting and angiogenic)12. TAMs are derived from circulating monocytes, which 
upon recruitment to the tumor microenvironment, adopt the M2 phenotype and orchestrate conditions influenc-
ing tumor  development22. The monocyte chemotactic protein-1, or CCL2, regulates polarization of M1 and M2 
phenotypes and recruits TAMs to the tumor  microenvironment23. CCL2 has been identified as a downstream 
target of β-catenin23. Furthermore, in vitro studies have shown that colon cancer cells stimulate macrophages 
to release IL-1β, which in turn enhances Wnt signaling in colon cancer cells, generating a self-amplifying loop 
promoting tumor  growth24.
Macrophage activation is also regulated by TBK1, which is a noncanonical IkB and Tank-binding kinase-1, 
which activates IFN regulatory factor 3 (IRF3) and NF-kB-dependent  genes25. Our current study showed that 
TBK1rs7486100 was strongly predictive of OS and PFS independent of KRAS status. TBK1 directly phosphoryl-
ates Akt signaling, and is an important downstream effector of  KRAS26,27. TBK1 is shown to be essential in some 
human cancer cell lines with KRAS  mutations28. Here, Barbie et al. show that suppression of TBK1 inhibited 
tumor formation in KRAS mutant cells, whereas suppression of TBK1 did not affect the tumorigenicity of KRAS 
wildtype colon cancer cells. Some studies have suggested the role of GSK-3β in activating  TBK129, which would 
present another interaction between the Wnt and TAM pathways. TBK-1 has also been shown to contribute to 
resistance to EGFR inhibitors via NF-κB signaling. Once TBK-1 activates NF-κB, this helps integrin avβ3 to con-
fer cell resistance to EFGR inhibitors, the exact mechanism of which is currently  unknown30. Hence, the strong 
predictive power of Wnt and TAM pathway SNPs in mCRC may lie in their complex interactions modulating the 
tumor microenvironment and angiogenesis, resulting in similar results observed in KRAS wildtype and KRAS 
mutant subgroups treated with bevacizumab-based chemotherapy.
Our RSF analysis identified DMRT1rs755383 SNP in the sex-differentiation pathway to strongly predict PFS 
in KRAS mutant patients. Polymorphisms in genes regulating sex differentiation have been shown to be predictive 
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of PFS and OS in KRAS  mutants31. KRAS mutant colorectal cancers show enhanced cancer stem cell pathways 
which accelerate  tumorigenesis32. This is the first study to report a relationship between the sex differentiation 
gene, DMRT1 and KRAS mutant in mCRC.
DMRT1 (doublesex and mab-3-related transcription factor 1) is a sex determination gene located on chro-
mosome  927, which serves as a tumor  suppressor33. It encodes a transcription factor that plays a key role in male 
sex determination and differentiation by controlling testis development and male germ cell  pluripotency34. In 
humans, several deletions in chromosome 9 have been associated with sex reversal and gonadal dysgenesis in XY 
 individuals35. DMRT1rs755383 is associated with the development of testicular germ cell  tumors36. The DMRT1 
pathway is intertwined with Wnt signaling, where Wnt activated SOX9 which activates  DMRT137. DMRT1 further 
inhibits SOX2, which is associated with a cancer stem cell state in colorectal  cancer38. There are many reports 
that Wnt/β-catenin pathways play important roles in the maintenance of cancer stem  cells39, which help confer 
resistance to EGFR  inhibitors40. Cancer cells with stem-cell properties develop resistance against tyrosine kinase 
inhibitors by expressing drug transporting proteins such as the ATP-binding cassette family (ABC) and facilitat-
ing epithelial-to-mesenchymal (EMT) transition. Hence, a stem cell state observed in KRAS mutant CRCs may 
be related to its relationship with DMRT1, which warrants further investigation as a target for drug development.
Our study had a few limitations. Firstly, differences in the locations and types of KRAS mutations between 
the two trials could have affected our results. Secondly, patients in FIRE-3 were only selected for KRAS exon 2 
wildtype status based on clinical evidence of response to cetuximab, and therefore, this cohort did not include 
alternate KRAS codons with wildtype status. Although KRAS exon 3 and 4 mutations are associated with resist-
ance to EGFR inhibitors, they interact with different pathways. For instance, exon 4 mutations are known to have 
Figure 5.  Kaplan–Meier curves and log-rank test for Wnt SNPs predictive of PFS and OS in KRAS wild-type 
and mutant mCRC patients: (A) KRAS wildtype patients with CBP rs129963 T/T variant have shorter PFS (9.5 
vs. 10.5 mo; p = 0.054) and (B) OS (22.8 vs. 26.1 mo; p = 0.048) compared to those with Any C allele. (C) KRAS 
mutant patients with β-catenin rs3864004 A/A genotype have shorter PFS (7.8 vs. 9.6 mo; p = 0.071) and (D) OS 
(16.3 vs. 26.3 mo; p = 0.008).
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MEK pathway  dependence41, which was not studied in our population. Hence, it is possible our study did not 
capture the heterogeneity in clinical outcomes due to the diversity of KRAS mutations. In addition, to increase 
the statistical power, we combined two independent trials, while the genetic difference may exist between two 
cohorts. Lastly, both trials included Caucasian patients, therefore, our results cannot be applied to an ethnically 
diverse population. The results of this study need to be validated in different patient populations.
It is important to note that the relationship between these pathways and KRAS is non-linear and involves 
complex interactions between multiple agents, including the tumor microenvironment, epigenetic regulation, 
multiple polymorphisms and unique cell physiology. This study offers a unique approach to exploring relation-
ships and interactions between multiple pathways, but the complex nature of the KRAS pathway cannot be 
understood by focusing on one pathway alone.
In summary, RSF is a useful method of identifying pathway interactions in high-dimensional settings to derive 
outcome data. In this study, we applied RSF to understand the genomic relationships between KRAS wildtype 
and mutant mCRC patients. We discovered that Wnt and TAM pathway SNPs might interact with each other to 
predict OS and PFS in mCRC treated with FOLFIRI/bevacizumab independent of KRAS status, whereas DMRT1 
SNP may be an important predictive marker in KRAS mutant patients. Our results suggest new pathways pre-
dictive of survival in the KRAS subgroups, and further understanding of these relationships may be useful for 
developing improved targeted treatments.
Figure 6.  Kaplan–Meier curves and log-rank test for TAM pathway SNPs predictive of PFS and OS in KRAS 
wild-type and mutant mCRC patients: (A) KRAS wildtype patients with TBK1 rs7486100 A/A variant have 
longer PFS (11.3 vs. 10.3 mo; p = 0.020) and (B) OS (31.3 vs. 24.8 mo; p = 0.040) compared to those with Any 
T allele. (C) KRAS mutant patients with TBK1 rs7486100 A/A genotype also have longer PFS (10.3 vs. 8.6 mo; 
p = 0.005). (D) TAM pathway SNP CCL2 rs4586 T/T carriers have longer OS (30.9 vs. 22.8 mo; p = 0.006).
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Figure 7.  Kaplan–Meier curve and log-rank test for angiogenesis pathway SNP, VEGFR2, predictive of OS in 
KRAS wild-type mCRC patients. Patients with VEGFR2 rs2305948 Any C carriers have significantly longer OS 
(26.2 vs. 17.0 mo; p = 0.001) compared to T/T carriers.
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Figure 8.  Kaplan–Meier curve and log-rank test for sex differentiation pathway SNP predictive of PFS in 
KRAS mutant mCRC patients. Patients with DMRT1 rs755383 Any T carriers have longer PFS (9.4 vs. 9.0 mo; 
p = 0.037) compared to C/C carriers.
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